Sanofi-aventis announced results from a new study that showed Ambien CR(R) (zolpidem tartrate extended-release) CIV tablets 12.5 mg provided significant improvement in sleep onset, sleep maintenance and total sleep time over 8 weeks in patients with co-morbid insomnia and major depressive disorder (MDD) who were administered a Selective Serotonin Reuptake Inhibitor (SSRI) for depression. Ambien CR also improved sleep-related next-day functioning measures.
Popularity: unranked [?]
Related posts:
- Blood Levels Of Paliperidone Extended-Release Tablets Are Not Increased By Common Antidepressant
- FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
- FDA Approves Wellbutrin XL(R) (bupropion HCl Extended-release Tablets) For The Prevention Of Seasonal Major Depressive Episodes
- Escitalopram Significantly Improves Quality Of Life In Major Depressive Disorder And Generalised Anxiety Disorder
- FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
Comments
No Responses to “Ambien CR(R) (zolpidem Tartrate Extended-release) CIV Tablets Improved Insomnia And Daily Functioning In Patients With Depressive Disorder”